Related Questions

The question given below consists of a statement, followed by three arguments numbered I, II and III. You have to decide which of the arguments is/are ‘strong’ arguments and which is/are ‘weak’ arguments and accordingly choose your answer from the alternatives given below each question. Statement: In the wake of globalization and digitization of the manner in which the business are conducted, the IT/ITES industry holds a significant place in the future business scenario. The Economic Survey 2017-18 mentioned that the IT/ITES services industry in India has scaled to around $140 billion during 2016-17. India today is globally the top outsourcing destination accounting for more than half of the market share. The IT/ITES industry has contributed around 7.7% of the country's GDP and according to IBEF is a key employment generator with a projection of creating 1.3-1.5 lakh new jobs annually. Which among the following arguments support the above statement in the best possible manner? Arguments: I. The Government has also provided considerable inputs to the industry with its various flagship programmes such as Digital India, Smart Cities, e-Governance coupled with a drive towards a cashless economy. II. The Government has been pro-active in considering demands of the industry and providing timely respite from the teething troubles under GST as well.  III. The IT/ITES industry is a labour intensive industry and a large scale employment generator. It is a common practice across the industry to provide various privileges and facilities to their staff in order to boost employee retention rates in their organisation.
In the question below, are given a statement followed by three courses of actions numbered I, II and III. On the basis of the information given, you have to assume everything in the statement to be true, and then decide which of the suggested courses of action logically follow(s) for pursuing. Statement: India’s pharmaceutical sector is now popping out from a shell and making a remarkable recovery. Actually, it has been facing several regulatory challenges in the forms of a recast of foreign direct investment (FDI) policy, pricing policy in the US generics market, patent protection, regulatory approvals and compulsory licensing. Also limited new product launches in the generics space, GST introduction and higher costs associated with regulatory compliance have hurt the sector. Courses of action: I. The government has been engrossed more in policy making and taking resilient decisions for the concerns of the pharma industry. Recently, the government proposed to introduce a new price index for pharmaceutical products, which would serve as a benchmark for determining prices of all medicines sold in the country. II. Meanwhile, pharma companies’ constant investments in R&D have enabled them to develop a basket of robust products for markets across the world. In international markets, pricing pressure on generics sold in the US has eased and this is likely to support the sector. III. Domestic pharma sales grew to Rs. 10,583 crore in May 2018 from Rs. 9,549 crore in the same month last year. The recent clearance by the US Food and Drug Administration to Sun Pharma’s manufacturing plant at Halol in Gujarat brings to an end a two-year import ban it had imposed on the company over quality issues. This is likely to increase sales for the company.